Generic colorful gummy candy, used to illustrate the gummy supplement format this story is about, not a photograph of Vitafusion's product or of NMN itself
Fumikas Sagisavas
Illustrative: generic gummy candy, not a photograph of Vitafusion's product or of NMN itself.
NMN Just Became a Mass Market Gummy, and the Newest Meta Analysis Found No Metabolic Benefit
NMN just crossed a real threshold. It is now sold as a mainstream drugstore gummy, not a niche capsule bought mostly by longevity minded biohackers who read the studies themselves. Vitafusion, the vitamin brand owned by Piping Rock Health Products, launched Vital NMN Gummies this month at 300 milligrams per serving, fronted by a TikTok first campaign called Aging? Love It. The timing is not an accident. The FDA spent years treating NMN as excluded from the legal definition of a dietary supplement, a status called drug preclusion, and only recently reversed course. The same season NMN becomes easy to buy at a checkout counter, the strongest current evidence summary on the ingredient says something quieter. NMN looks safe, and it has not been shown to do the metabolic things its marketing implies.
- Vitafusion, now owned by Piping Rock, launched Vital NMN Gummies with 300 milligrams of NMN per serving, backed by a TikTok first Aging? Love It. campaign, after the FDA reversed the drug preclusion rule that had kept NMN out of supplements since 2022.
- A meta analysis of 15 randomized trials, published in July 2026, found NMN did not raise liver enzymes or the rate of any adverse event, so current evidence points to short term safety.
- The same meta analysis found no significant effect on body weight, fasting glucose, HbA1c, or cholesterol. Only diastolic blood pressure fell slightly.
- NMN reliably raises NAD+ in the blood. It has not been shown to do the metabolic things a gummy marketed for aging, energy, and metabolism implies.
What 15 trials actually found
A July 2026 systematic review and meta analysis in the journal Nutrients pooled 15 randomized controlled trials of oral NMN, with doses ranging from 250 to 2,000 milligrams a day and durations from 14 days up to 24 weeks. Ten of those trials had enough safety data to pool. Across them, NMN did not increase the overall rate of adverse events, serious adverse events, withdrawals, or system specific side effects, and it did not raise ALT or AST, the standard liver enzyme markers. That is the safety half of the picture, and it looks reassuring. The metabolic half looks different. Pooling the trials found no significant effect on body weight, BMI, fasting glucose, HbA1c, or lipids. Systolic blood pressure did not move either. Diastolic blood pressure fell slightly, and a measure of insulin resistance called HOMA IR trended downward without reaching statistical significance. The authors describe these two findings as preliminary vascular metabolic signals that need larger, longer trials before anyone can call them real effects.
A gummy that borrows a claim its own trials do not support
Vitafusion's Vital NMN Gummies deliver 300 milligrams of NMN per serving, comfortably inside the dose range the trials above actually tested. The product is marketed for NAD+ levels, cellular health, vitality and repair, energy, and metabolism. NAD+ levels are the one claim the evidence solidly backs. NMN raising NAD+ in the blood is well documented and not in dispute. Metabolism is the word doing the marketing work here, and it is the word the meta analysis specifically failed to support. This launch also depends on a regulatory reversal most readers have not heard about. In 2022 the FDA excluded NMN from the legal definition of a dietary supplement, a decision known as drug preclusion, after a drug company had already studied NMN first. The agency reversed that position, and by December 2025 it was acknowledging individual manufacturer notifications for NMN as a new dietary ingredient. Acknowledging a notification is a procedural step. It is not a safety or efficacy determination, and it does not mean the FDA has evaluated Vitafusion's product specifically.
Honest caveat
The meta analysis pools NMN and NMN related preparations together, and includes some trials from Chinese databases, CNKI and Wanfang, alongside the usual international registries. Most of the individual trials are small and short, several under three months. A figure reported in trade coverage, that 383 participants were included in the safety analyses, does not actually appear in the paper's own abstract, so it is treated here as unconfirmed. A null result on metabolism is not the same as proof that NMN does nothing. NAD+ elevation itself is real and repeatedly measured. What remains unproven is whether raising NAD+ this way changes anything a reader would actually feel or a lab test would actually catch. And the launch facts here, the dose, the campaign, the framing, come from Vitafusion's own press release, an interested source describing its own product.
What this means for you
If you already take NMN, this is reassuring on safety and unchanged on benefit. Fifteen trials running up to six months found no red flags. If you are considering the Vitafusion gummy specifically because of the marketing around aging, energy, or metabolism, the honest answer is that the best current evidence does not back the metabolic claims, even though the dose itself is a normal one. A gummy is also a different delivery format than the capsules and sublingual powders most of the underlying trials tested, so it is fair to ask a company for third party testing before trusting a printed number on a candy sized dose. If NAD+ elevation itself is what you are after, the trials support that NMN does raise it. What you should not assume is that a higher NAD+ number translates into a lower blood sugar number, a lower weight, or a longer life. Nobody has shown that yet.
Primary sources
- Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and Metabolism Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta Analysis. Nutrients, 2026;18(14):2251.
- Vitafusion Says Aging? Love It. With Launch of Vital NMN Gummies. PR Newswire, September 2026.
- FDA letter on NMN new dietary ingredient notification, December 2, 2025 (cited via Nutritional Outlook, September 21, 2026).
Common questions
Is NMN safe to take?
The best current evidence, a pooled analysis of 15 randomized trials running up to 24 weeks at doses from 250 to 2,000 milligrams a day, found no increase in adverse events, serious adverse events, or liver enzyme changes. That points to short term safety. No trial in the analysis ran longer than six months, so longer term safety has not been established.
Does NMN actually help with weight, blood sugar, or cholesterol?
Not according to the newest meta analysis. Pooling 15 trials found no significant effect on body weight, BMI, fasting glucose, HbA1c, or cholesterol. Diastolic blood pressure fell slightly, which the study authors called a preliminary signal that needs confirmation in larger, longer trials, not an established benefit.
Why is NMN suddenly available as a gummy at the drugstore?
The FDA had excluded NMN from the legal definition of a dietary supplement since 2022, a status called drug preclusion. The agency reversed that position, and by December 2025 was acknowledging individual manufacturer notifications for NMN as a new ingredient. That procedural shift, not any new safety or efficacy finding, is what cleared the way for mass market launches like Vitafusion's.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.